ORLANDO, FLORIDA—Patients with low-risk prostate cancer are more likely to die with their disease than of it, according to Dr Ayal Aizer from the Brigham and Women’s Hospital, the Dana-Farber Cancer Institute and Harvard University in Boston MA — a merit-award winner at the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO) 2013 Genitourinary Cancers Symposium. Treatment with surgery or radiotherapy, he noted, adds toxicity with the potential to do harm without bringing any additional mortality benefit, for the majority of these patients.
You may also like...
Audio Journal of Oncology Volume 16 Number 10 25 May, 2008 New Strategies for Preventing ER-Negative Breast Cancer 23 Mar, 2015 Audio Journal of Oncology in Advance – April 15th, 2007 – Bisphosphonates Recommended for Lung Cancer Bone Metastases 15 Apr, 2007 The Disappointment of the NSABP C-08 Trial 16 Sep, 2009
- Previous story Androgen Blockade: 18 As Good As 36 Months In Radiotherapy-Treated Prostate Cancer
- Next story Low risk localized prostate cancer: no harm from waiting!
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014